INTRAVENOUS THROMBOLYTIC THERAPY FOR ACUTE ISCHEMIC STROKE - WEIGHINGTHE RISKS AND BENEFITS OF TISSUE-PLASMINOGEN ACTIVATOR

Authors
KOLLER RL ANDERSON DC
Citation
Rl. Koller et Dc. Anderson, INTRAVENOUS THROMBOLYTIC THERAPY FOR ACUTE ISCHEMIC STROKE - WEIGHINGTHE RISKS AND BENEFITS OF TISSUE-PLASMINOGEN ACTIVATOR, Postgraduate medicine, 103(4), 1998, pp. 221
Citations number
10
Categorie Soggetti
Medicine, General & Internal
Journal title
Postgraduate medicine → ACNP
ISSN journal
00325481
Volume
103
Issue
4
Year of publication
1998
Database
ISI
SICI code
0032-5481(1998)103:4<221:ITTFAI>2.0.ZU;2-H
Abstract
The use of intravenous tPA within 3 hours after acute ischemic stroke has been proved to increase the number of good outcomes. However, tPA is a toxic therapy that carries a substantial risk of intracerebral he morrhage. To decrease the risk, tPA use must be restricted to a carefu lly selected patient population. Treatment must be administered in an intensive care setting and directed by physicians with expertise in di agnosing and managing stroke.